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Comparing the embolic potential of open and
closed cell stents during carotid angioplasty and
stenting
Rami O. Tadros, MD, Constantinos T. Spyris, BA, Ageliki G. Vouyouka, MD, Christine Chung, MD,
Prakash Krishnan, MD, Margaret W. Arnold, MD, Michael L. Marin, MD, and Peter L. Faries, MD,
New York, NY
Objective: We sought to determine the effects of open (O) and closed (C) cell stents on the size and number of embolic
particles generated during carotid artery stenting (CAS) and assess the impact on outcome.
Methods:Embolic debris from carotid filters after CASwas analyzed using photomicroscopy and imaging software. Patient
comorbidities, preoperative cerebrovascular symptoms, stent type, and outcomes (perioperative major adverse events)
were examined.
Results:Carotid filters from 173 consecutive CAS procedures (O, 125 andC, 48) were reviewed. Themean age was 70.9
9.2 years; 58%were men.Mean stenosis was 88.2% 8.1%; 36.6% had neurological symptoms preprocedurally. There was
no difference in preoperative symptoms between the two groups (O, 38.7% vs C, 31.3%; P  not significant [NS]).
However, closed cell stent use was associated with higher degree of stenosis (O, 87.2%  8.0% vs C, 90.6%  7.8%; P 
.01), an older age (O, 70.0 8.6 years vs C, 73.4 10.2 years; P .03), and peripheral arterial disease (21.1% vs 43.5%;
P  .01). A larger mean particle size was observed in patients treated with open cell stents compared to closed cell stents
(O, 416.5  335.7 m vs C, 301.1  251.3 m; P  .03). There was no significant difference in the total number of
particles (O, 13.8 21.5 vs C, 17.6 19.9; PNS), periprocedural stroke (PNS), and major adverse events between
the two groups (P  NS).
Conclusions: Open cell stents are associated with a larger mean particle size compared to closed cell stents. No impact on
procedural outcomes based on stent type was observed. (J Vasc Surg 2012;56:89-95.)
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cCarotid endarterectomy (CEA) is an effective and well-
established method of reducing stroke and death rates
when compared to best medical therapy.1-4 Carotid artery
stenting (CAS) has been established as an alternative to
CEA in select patient populations that are at an increased
surgical and/or cardiopulmonary risk.5,6 Although less in-
vasive, CAS results in more cerebrovascular sequelas than
CEA.7-9 Therefore, CEA is still the preferred mode of
carotid revascularization in the majority of patients with
symptomatic and asymptomatic carotid stenosis who reach
the treatment threshold.
To establish the non-inferiority of CAS compared to
CEA, a reduction in the transient ischemic attack (TIA),
stroke, and death rates to a level comparable to CEA must
be demonstrated. To date, CAS has failed to meet this
benchmark. Identifying variables that increase the risk of
distal embolization during CAS and postprocedurally is
essential. Modifying these risk factors is necessary to reduce
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Carotid stent design has been proposed as a potential
odifiable risk factor and contributor to embolic risk.
pecifically, comparisons of open and closed cell stent
esigns, defined by the free cell area between stent lattices,
ave been performed in several retrospective analyses and a
ingle underpowered randomized control trial.10-17 How-
ver, the results of these studies are not uniform and have
erived varying conclusions. Therefore, there is no consen-
us on which stent design is preferable. Nevertheless, mod-
fying carotid stent structure, composition, and geometry
as the potential to improve CAS outcomes to an accept-
ble level comparable to CEA.
In our study, we sought to determine the effects of
pen and closed cell stent designs on the size and number
f embolic particles generated during CAS. Further, we
ssessed the impact of open and closed cell stents on
eriprocedural and postprocedural outcomes.
ETHODS
A retrospective review of 251 consecutive CAS proce-
ures from 2003 to 2010 was performed. Of these proce-
ures, 188 carotid embolic protection devices (EPDs), 181
f them being filters and 7 balloon devices, were collected,
nalyzed, and maintained in a prospective database. Stent
ype was known for 173 of the analyzed EPDs. Debris
aptured from the 173 CAS procedures was examined and
sed in the analysis. Thirteen of these procedures were from
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July 201290 Tadros et alpatients with bilateral CAS, and one was from a patient with
a second CAS performed ipsilaterally due to a stenosis
proximal to the original stent. The excluded devices from
the 251 procedures included EPDs that had not been
collected after the procedure, the stent used was unknown,
those where no particle data was recorded, and those that
used embolic protection that did not allow for collection of
particles such as flow reversal devices.
The technique of handling and analyzing the captured
filter debris has been described before.18 Intraprocedural
systemic anticoagulation is used to prevent in situ filter
thrombosis. Postprocedurally, with the filter maintained in
the upright position, the external surface of the filter is
wiped clean using saline-moistened gauze. Two or three
drops of normal saline is placed inside the filter and drawn
through the pores using gauze applied to the external
surface to help particulate precipitate within the filter.
Filters are fixed in 1% neutral buffered formalin solution.
The particulate matter is then examined using photomi-
croscopy. Using this technology, in conjunction with video
imaging software, the size and number of particles captured
in each filter are recorded. These counts and measurements
are performed along three perpendicular axes. The length
along the longest axis of each particle is used to determine
each particle size (Fig 1). The method for balloon protec-
tion device particle retrieval has also been described be-
fore.19 Briefly, an aspiration catheter with a vacuum syringe
is advanced toward the occlusion balloon and retracted
several times with suction applied until 20 mL of blood was
aspirated. All EPD particle debris was analyzed by two
independent viewers, and discrepancies in particle number
and size were resolved by averaging.
Patient selection for CAS was based on clinical charac-
teristics placing them at increased risk for standard CEA
which included medical comorbidities (Goldman class II or
III,20 American Society of Anesthesiologists class III or
IV21), increased cardiopulmonary risk, contralateral carotid
artery occlusion, high lesion location in the internal carotid
Fig 1. Captured particles martery, restenosis after prior ipsilateral CEA, or anatomic uactors such as a history of neck irradiation, neck dissection,
r spinal immobility with inability to extend the neck
eyond a neutral or kyphotic deformity.22,23 Contraindica-
ions to CAS included angiographic evidence of excessive
esion calcification, severe vascular tortuosity, small internal
arotid artery diameter precluding stent placement, and an
nability to use clopidogrel.
The patient population was analyzed as a whole and
tratified by the type of stent used and whether the stent
sed was open or closed cell. Symptomatic patients were
dentified as those with a cerebrovascular accident (CVA),
IA, or amaurosis fugax (AF) within 90 days of CAS.
atients with coronary artery disease (CAD) were defined
s those with a history of myocardial infarction (MI),
oronary artery bypass grafting, or angina. Renal insuffi-
iency was defined to include chronic renal insufficiency
creatinine 1.5 mg/dL) and end-stage renal disease.
eriprocedural CVA was defined as focal neurological def-
cit lastingmore than 24 hours with new lesions detected by
omputed tomography or magnetic resonance imaging.
eficits lasting 24 hours were categorized as a TIA. MI
as defined as any cardiac enzyme leak positive three times,
nd mortality was defined as any death from the day of the
rocedure until 30 days afterward. Technical success was
efined as successful delivery and deployment of the stent
nd the presence of antegrade flow on intraprocedural
ngiography.
CAS was performed using local anesthesia with no
edation to minimal sedation to monitor the patient’s neu-
ological status throughout the procedure. This technique
as been described before.24,25 Vascular access was
chieved through the common femoral artery. Cerebral
ngiography was used to verify the degree of carotid artery
tenosis and to assess the baseline and postprocedure intra-
ranial circulation. An activated clotting time of 250
econds was maintained with intravenous unfractioned
eparin. Clopidogrel 75 mg for 5 days before CAS or a
ingle 300 to 450 mg loading dose 4 hours before CAS was
red along the longest axis.sed. Multiple types of stents and EPDs were used during
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Volume 56, Number 1 Tadros et al 91the study period reflecting the evolving technology and
availability of contemporary devices. Lesions were routinely
predilated at the operator’s discretion usually using a 4- 
30-mmor 4- 50-mm angioplasty balloon and postdilated
typically with a 5- to 6-  20-mm angioplasty balloon.
Smaller caliber angioplasty balloons were used selectively.
Glycopyrrolate (0.2 to 0.4 mg) was routinely administered
before predilation. Before 2006, atropine 0.5 mg was used.
Patients were maintained on 325 mg of aspirin and 75 mg
of clopidogrel daily during the postoperative period. Clopid-
ogrel was normally discontinued after 30 days, and aspirin
was maintained indefinitely.
Statistical analyses were performed with the Fisher ex-
act test for categorical variables and t-tests were used for
continuous variables withWelch corrections if the variances
of the groups were not equal. Values were expressed as a
mean SDwhere applicable and statistical significance was
defined as P  .05. Analyses were performed with SPSS
Statistics, version 17.0 (SPSS, Chicago, Ill).
The ethics committee and internal review board of
Mount Sinai School of Medicine approved the study pro-
tocol.
RESULTS
Of the 251 CAS procedures performed, 173 EPDs had
a known stent type and configuration. Open cell stents were
used in 125 cases (72.3%), and 101 patients (58.4%) were
men. The mean age was 70.9  9.2 years (range, 48-94
years), and the mean percent stenosis of the internal carotid
artery as determined intraoperatively by angiography was
88.2%  8.1% (range, 60%-99%). Closed cell stents were
associated with an older patient age (73.4  10.2 vs 70 
8.6; P .03) and a greater degree of angiographic stenosis
(90.6  7.8 vs 87.2  8.0; P  .01). Preoperative neuro-
logic symptoms were present in 63 (36.4%) of the cases; 17
(9.8%) had a CVA only, 29 (16.8%) had a TIA only, seven
(4.0%) had AF only, four (2.3%) had combined CVA and
TIA, one (0.6%) had combined CVA and AF, and three
(1.7%) had combined TIA and AF. All of the procedures
achieved technical success.
The clinical characteristics of patients that received
open cell vs closed cell stents are in Table I. The patient
groups were similar except for an increased rate of preop-
erative TIA (25.2% vs 10.4%; P  .01), an increased prev-
alence of chronic obstructive pulmonary disease (22.9% vs
2.2%; P  .001), and a decreased prevalence of peripheral
arterial disease (21.1% vs 43.5%; P  .01) in the patients
who received open cell stents (Table I). Additional clinical
characteristics, including CAD, congestive heart failure
(CHF), diabetes mellitus (DM), hyperlipidemia, hyperten-
sion (HTN), neck irradiation, prior ipsilateral CEA, renal
insufficiency, and smoking, were analyzed looking for dif-
ferences in the total number and mean size of particles.
There were no significant differences among these variables
between the two groups. Particle analysis comparing open
cell and closed cell stents showed no difference in the total
number of particles captured byEPDs (13.821.5 vs 17.6
19.9; P .30; Fig 2). Open cell stents were associated with wsignificantly larger mean particle size (416.5 335.7 m
s 301.1 251.3 m; P .03; Fig 3) in contrast to closed
ell stents.
Of the 173 procedures, there were two (1.2%) peripro-
edural CVAs which both occurred with closed cell stents
Table II). The first patient was an 86-year-old man with
ultiple comorbid illnesses (CHF, arrhythmia, angina,
moker, and peripheral vascular disease) who presented
ith a CVA. This individual had a periprocedural stroke
able I. Clinical characteristics of open vs closed cell
tents
Open Closed
P
value
No. of
patients (%)
No. of
patients (%)
ge, mean  SD 70.0  8.6 73.4  10.2 .029
ercent stenosis, mean  SD 87.2  8.0 90.6  7.8 .014
ale gender 70 (56.0) 31 (64.6) .31
ight side 61 (48.8) 24 (50.0) .89
ny neurological symptoms 48 (38.7) 15 (31.3) .36
VA 14 (11.4) 8 (16.7) .36
IA 31 (25.2) 5 (10.4) .014
F 9 (7.3) 2 (4.2) .45
AD 74 (59.2) 29 (60.4) .89
HF 14 (11.4) 5 (10.9) .93
OPD 27 (22.9) 1 (2.2) .001
M 41 (32.8) 21 (43.8) .20
yperlipidemia 88 (71.5) 32 (69.6) .80
TN 108 (87.8) 43 (91.5) .50
eck XRT 16 (12.9) 4 (8.7) .45
rior ipsilateral CEA 17 (13.9) 7 (15.2) .83
AD 26 (21.1) 20 (43.5) .01
enal disease 16 (12.8) 2 (4.2) .10
moking 80 (65.0) 29 (61.7) .69
F, Amaurosis fugax;CAD, coronary artery disease;CEA, carotid endarter-
ctomy; CHF, congestive heart failure; COPD, chronic obstructive pulmo-
ary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; HTN,
ypertension; PAD, peripheral arterial disease; TIA, transient ischemic
ttack; XRT, prior irradiation.
ig 2. When comparing open and closed cell stents, no difference
n the mean number of particles captured by embolic protection
evices (EPDs) was observed.ithout lasting deficits. The EPI FilterWire (Boston
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July 201292 Tadros et alScientific Corp, Natick, Mass) and Nexstent (Boston
Scientific Corp) were used in this patient, and particle
analysis revealed one large particle which measured 1320
m. The second patient was an 83-year-old man who also
had multiple comorbidities (angina, arrhythmia, CAD,
DM, dyslipidemia, smoker, and HTN). He initially pre-
sented with a CVA and subsequently had both a peripro-
cedural MI and CVA. The EPI FilterWire and Wallstent
(Boston Scientific Corp) were used in this patient. Analysis
of this patient’s filter identified 52 particles with a mean size
of 663 m. These numbers, relative to our study popula-
tion, are dramatically greater than our observed means.
Additionally, there was one other MI which occurred with
a closed cell stent (Wallstent with an EPI FilterWire) for a
total of two MIs (1.2%), and one mortality (0.6%) which
occurred with the use of an open cell stent (Protégé stent
[ev3 Inc, Plymouth, Minn] with a Spider EPD [ev3 Inc];
Table II).
DISCUSSION
The treatment of extracranial cerebrovascular disease is
plagued with controversy. In the 1990s, landmark random-
ized control clinical trials were conducted comparing CEA
to best medical therapy. For those that reach the threshold
stenosis, CEA has consistently shown a reduction in stroke
and death rates in symptomatic and asymptomatic individ-
uals.1-4 More recently, the quest for minimally invasive
approaches to treat traditionally surgical diseases and the
Fig 3. Open cell stent design associated with a larger mean par-
ticle size.
Table II. Major adverse events
Open cell Closed cell P value
MI 0 2 .16
CVA 0 2 .16
Mortality 1 0 .54
Combined MI/CVA/mortality 1 3 .14
CVA, Cerebrovascular accident; MI, myocardial infarction.advancement of endovascular therapies and techniques has sotentiated the development of CAS. Although less inva-
ive, CAS has not shown equipoise when compared to
ndarterectomy.7-9 For CAS to truly achieve equivalence or
uperiority, the stroke and death rates must be comparable
o endarterectomy.
Before the introduction of EPDs, neurologic compli-
ations after CAS were prohibitive. These adverse out-
omes sparked investigations aimed at understanding and
reventing atheroembolization related to carotid stenting.
he need for embolic protection, safe device delivery, and
echnical competency became evident. Embolic protection
ystems improved the safety of CAS and heightened inter-
st in this procedure.18,19,25
Although improved after the implementation of em-
olic protection, CAS outcomes remain inferior when
ompared to endarterectomy. An abundance of random-
zed trials have been conducted comparing CAS and CEA
utcomes. Independently, the Endarterectomy vs Angio-
lasty in Patients with Symptomatic Severe Carotid Stenosis
EVA-3S), Stent-Protected Angioplasty vs Carotid Endarter-
ctomy (SPACE), Carotid and Vertebral Artery Transluminal
ngioplasty Study (CAVATAS), Carotid Revascularization
ndarterectomy vs Stenting Trial (CREST), and Interna-
ional Carotid Stenting Study (ICSS) all failed to demonstrate
n overall advantage of CAS over CEA.4,6,26-31 An analysis of
ooled data from the EVA-3S, SPACE, and ICSS clearly
emonstrated an overall higher periprocedural risk of
troke and death with CAS compared to endarterectomy.8
urther stratification localized the higher periprocedural
troke and death rates to patients over 70 years of age
12.0% vs 5.9%; P .0053).8 A similar increased stroke risk
n patients 70 years of age was found in the CREST.6 In
ddition, CREST demonstrated reduced stroke rates with
EA, but an increased risk ofMI when compared to carotid
tenting. Further, a large meta-analysis by Bangalore et al,9
eviewing 13 randomized clinical trials and incorporating
he outcomes of 7477 patients, demonstrated that patients
ith CAS had less MIs and cranial nerve deficits, but higher
ates of stoke or death compared to CEA. In this meta-
nalysis, CEA had superior outcomes overall. Understand-
bly, for CAS to establish pre-eminence, the stroke and
eath rates after stenting must improve while maintaining
he known benefits of this treatment.
In our current review, we report two periprocedural
trokes after CAS, both of which occurred in octogenarians
eing treated after having a CVA. Although the risk of
eriprocedural stroke and death after CAS is higher in this
ge group compared to endarterectomy, these patients
resented with severe cardiac comorbidities that precluded
n open surgical approach. Given the prohibitive risk of a
EA and the symptomatic nature of their presentation,
arotid stenting was felt to be the best treatment option.
Reducing atheroembolic complications after CAS is
ot limited to the use of EPDs. Stent characteristics and
rocedural factors influence the risk of distal embolization
nd, as a result, affect neurologic outcomes. Embolic debris
s generated at multiple stages when performing carotid
tenting. Passing wires and catheters, advancing EPDs,
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Volume 56, Number 1 Tadros et al 93performing angioplasty, and stent deployment can all result
in emboli as a consequence of manipulating atherosclerotic
vessels. This embolic potential was clearly exemplified by
Bonati et al32 in a study using pre-procedure and post-
procedure diffusion-weighted magnetic resonance imaging
to assess for cerebrovascular sequelas after carotid stenting.
When compared to CEA, patients undergoing CAS had
three times the number of new ischemic lesions on post-
procedure imaging.
Ideally, carotid stents should have low-profile delivery
systems. These stents require conformability and tractabil-
ity. Although malleable, carotid stents must have sufficient
radial force to prevent stent collapse or vessel recoil and
durability to resist material fatigue or fracture. Further,
these stents must deploy easily with minimal foreshorten-
ing. The stent lattices must scaffold plaque and allow easy
retrieval of embolic protection filters. Currently, carotid
stents are predominately composed of nitinol, a nickel
titanium alloy. Nitinol’s shape memory, elastic properties,
and resilience are suited for carotid stenting.33,34 However,
alternative materials especially suited for this purpose may
generate improved outcomes.
Carotid stent designs are categorized as open or closed
cell based on the free cell area between stent lattices (Table
III).10 Open and closed cell stents have important mechan-
ical and structural differences.34-36 Closed cell stents are
more tightly woven and therefore have a smaller free cell
area. Consequently, this design is stiffer and less conform-
able in tortuous vessels. These characteristics can compli-
cate stent delivery. Further, stent rigidity may induce arte-
rial kinks due to straightening a curved structure.
Conversely, due to a larger free cell area, open cell stents
readily navigate serpentine vessels. Moreover, the flexible
nature of open cell stents helps avoid unnecessary straight-
ening. Theoretically, closed cell stents are advantageous in
select cases due to an improved ability to scaffold plaque.
This scaffolding effect may reduce distal embolization in
individuals with a high embolic risk.34 In an ex vivo model
by Muller-Hulsbeck et al,36 stents were bent to 20 and 30
degrees, and torque was applied between 10 and 15 de-
grees. Closed cell stents generated higher forces when
bowed and twisted. This study also showed that the free cell
area can vary along the proximal, middle, and distal por-
tions of the stent when contorted. This variability seems
Table III. Stents deployed during carotid stenting
Type of
stenting Stent brand
No. of
patients
Free cell
area (mm2)
Closed Wallstent 37 1.1
Xact 8 2.7
NexStent 3 4.7
Open Precise 15 5.9
Protégé 36 10.7
Acculink 74 11.5
As reported by Bosiers et al.10more pronounced in open cell configurations. Such un- pvenness may offer different levels of embolic protection
long various sectors of the stent. Comparatively, this
ench-top example illustrated that open cell stents allowed
enetration of larger spheres. These findings may be ap-
lied in future stent designs to allow a balance of scaffolding
nd flexibility. An additional speculative benefit of closed
ell stents is decreased platelet aggregation. Gurbel et al37
emonstrated this finding in an ex vivo porcine model. This
bservation may perhaps result from less intimal prolapse
nd smoother stent apposition against the arterial wall seen
ith closed cell stents. Another important consideration,
pecifically during postprocedural surveillance, is that stent
esign will influence the results of duplex ultrasound scans.
ussain et al38 demonstrated that the peak systolic veloci-
ies and internal carotid/common carotid artery ratios were
ignificantly higher in closed cell stents.
Despite the hypothetical advantage of plaque stabiliza-
ion, closed cell stents do not consistently cause less
eriprocedural neurological events when compared to
pen cell stents. A consensus regarding an ideal stent
onfiguration and a clear improvement in outcomes have
ot been uniformly demonstrated. Large prospective ran-
omized control studies have not been performed compar-
ng open and closed cell stents. Several retrospective,
utcome-based studies and one low-powered randomized
ontrol trial have been performed comparing stent designs
Table IV). Bosiers et al10 and Hart et al14 independently
howed improved outcomes when using closed cell stents
n patients treated for symptomatic carotid disease. These
enefits were not realized in their asymptomatic counter-
arts. On the contrary, in a retrospective study comparing
tent designs by Blasel et al,13 diffusion-weighted magnetic
esonance imaging results after CAS in symptomatic pa-
ients showed no difference in the number of newmagnetic
esonance imaging lesions. Additional retrospective studies
y Maleux et al,12 Schillinger et al,11 and Jim et al,16 and
ne small randomized control trial by Timaran et al17
omparing stent designs in mixed populations of symptom-
tic and asymptomatic patients failed to show improved
utcomes based on the stent type used.
In an effort to further understand the risk of periproce-
ural neurologic events, we investigated the affect of ca-
otid stent design on the number and size of embolic
able IV. Comparing studies that assessed impact of
tent design
tudy
No. of
patients
Favoring closed
cells stents
No difference
observed
lasel et al13 84 X
osiers et al10 3179 X
art et al14 304 X
aleux et al12 123 X
chillinger et al11 1684 X
imaran et al17a 40 X
im et al16 4337 X
Randomized control clinical trial.articles captured by EPDs during carotid stenting. Fur-
11
1
1
1
1
1
1
1
1
2
2
2
2
2
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July 201294 Tadros et alther, we compared periprocedural and postprocedural out-
comes. Based on our data comparing open and closed cell
stents, there was no observed difference in the total number
of embolic particles generated during CAS. However, the
use of an open cell stent was associated with an overall
larger average particle size. Subsequent analysis also found
a positive correlation between the free cell area and mean
particle size. Larger embolic particles in theory may result
in more severe and substantial cerebrovascular complica-
tions. Further, quantifying the number and size of particles
captured during CAS may act as a surrogate for postproce-
dural outcomes. Analysis of EPDs from the two patients
with periprocedural strokes revealed an excess of debris
and larger caliber particles compared to the total popu-
lation. The utility of these observations has not been
fully established.
Several limitations to this study exist. Patients with
severe vascular tortuosity and calcification were not consid-
ered candidates for carotid stenting. In addition, the total
number of EPDs analyzed was small and portions of data
were excluded from our analysis due to incomplete infor-
mation. Although likely underpowered, our study showed
no difference in major adverse events between the two
groups.
CONCLUSIONS
Reducing CAS embolic complications to a level com-
parable to CEA is necessary to broaden the indications of
carotid stenting. The free cell area of the stent used during
CAS may influence procedural outcomes; however, a con-
sensus based on the available data cannot be construed.
Large prospective randomized control trials are necessary
to help delineate potential benefits relating to stent design.
A selective approach to the use of closed cell stents when
the embolic potential is high and the use of open cell stents
in tortuous anatomy may be the best strategy pending
further investigation.
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